REPL

Replimune Group, Inc. (REPL) - 10-K Summary

Business Context and Reporting Period

Company: Replimune Group, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 31, 2026
Business Overview: Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies based on its proprietary RPx platform. The lead product candidate, RP1 (vusolimogene oderparepvec), is in development for advanced melanoma and other skin cancers. The company operates an in-house manufacturing facility in Framingham, Massachusetts.

Key Financial Metrics

Note: The company has not generated any revenue from product sales to date.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by 27% to $313.9 million, driven by higher operating expenses.
• R&D Expense Growth: R&D expenses rose 17% to $221.2 million. This was primarily due to a $13.9 million increase in RP2 study costs (REVEAL study) and a $12.9 million increase in RP1 costs (IGNYTE-3 confirmatory study and other study costs).
• SG&A Expense Growth: SG&A expenses increased 37% to $98.7 million, largely due to a $20.3 million increase in personnel-related costs as the company hired staff to prepare for a potential commercial launch.
• Debt Increase: Long-term debt increased significantly following a $35.0 million drawdown under the Hercules Loan Agreement in January 2026.
• Cash Position: Cash and short-term investments decreased by approximately $215 million year-over-year due to operating cash burn, partially offset by financing activities.

Guidance, Outlook, Risks, and Unusual Items

Regulatory Status and Outlook

• RP1 BLA Status: The FDA issued a second Complete Response Letter (CRL) on April 10, 2026, regarding the Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma. The CRL reiterated concerns regarding the adequacy of the IGNYTE trial data.
• Path Forward: Following collaborative communications, the FDA accepted a Class 1 resubmission of the BLA on June 26, 2026, with an action date of August 2, 2026. An FDA advisory committee meeting is scheduled for late July 2026.
• Restructuring: In April 2026, the company announced a restructuring plan including a workforce reduction of approximately 55% (from 465 employees) to reduce cash burn. A subsequent event note indicates an estimated charge of $9.8 million to $10.3 million for termination benefits.
• Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Management estimates existing cash resources will fund operations only into the first quarter of calendar 2027. Additional financing will be required.

Risks and Contingencies

• Regulatory Risk: Failure to obtain FDA approval for RP1 could force the company to terminate development, implement further restructuring, or seek strategic alternatives.
• Litigation: A class action lawsuit (Jboor v. Replimune Group, Inc.) was filed in July 2025 following the first CRL. An SEC investigation into the BLA was concluded in June 2026 with no enforcement action recommended.
• Capital Needs: The company has no committed external funding sources and must raise additional capital to continue operations beyond Q1 2027.

Key Facts for Investor Verification

• BLA Resubmission Timeline: Verify the outcome of the FDA advisory committee meeting (late July 2026) and the final action on the RP1 BLA (August 2, 2026).
• Restructuring Execution: Monitor the completion of the 55% workforce reduction and the actual financial impact of the estimated $9.8M–$10.3M restructuring charge.
• Cash Runway: Assess the company's ability to secure additional financing before the projected cash exhaustion in Q1 2027.
• Debt Covenants: Review compliance with the Hercules Loan Agreement covenants, specifically the requirement to maintain unrestricted cash levels relative to outstanding debt.
• RP2 Development: Track progress of the REVEAL study for RP2 in metastatic uveal melanoma, which is a key diversification effort if RP1 approval is delayed or denied.